FLACU
Frazier Lifesciences Acquisition Corporation [FLACU] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
FLACU Stock Summary
In the News
FLACU Financial details
Company Rating
Sell
Market Cap
0
Income
-2.18M
Revenue
0
Book val./share
-0.82
Cash/share
0.03
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
-32.14
Forward P/E
-
PEG
-0.1
P/S
-
P/B
-12.1
P/C
-
P/FCF
-
Quick Ratio
0.1
Current Ratio
0.12
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.22
EPS next Y
-
EPS next Q
-
EPS this Y
-7846.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
1956.45%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-3%
ROE
-5%
ROC
-0.03%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.07-10.8
52W High
-
52W Low
-
RSI
-
Rel Volume
4.05
Avg Volume
4.49K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
FLACU Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2020-12-31 | 2021-12-31 |
|---|---|---|---|
| 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | |
| Net income per share | -0.01 | 0.55 | |
| Operating cash flow per share | 0 | -0.01 | |
| Free cash flow per share | 0 | -0.01 | |
| Cash per share | 7.85 | 0.07 | |
| Book value per share | 7.59 | 7.42 | |
| Tangible book value per share | 7.59 | 7.42 | |
| Share holders equity per share | 7.59 | 7.42 | |
| Interest debt per share | 0 | 0 | |
| Market cap | 191.71M | 173.07M | |
| Enterprise value | 190.34M | 171.85M | |
| P/E ratio | -1.51K | 17.77 | |
| Price to sales ratio | 0 | 0 | |
| POCF ratio | 0 | -1.25K | |
| PFCF ratio | 0 | -1.25K | |
| P/B Ratio | 1.42 | 1.31 | |
| PTB ratio | 1.42 | 1.31 | |
| EV to sales | 0 | 0 | |
| Enterprise value over EBITDA | -1.5K | 40.97 | |
| EV to operating cash flow | 0 | -1.24K | |
| EV to free cash flow | 0 | -1.24K | |
| Earnings yield | 0 | 0.06 | |
| Free cash flow yield | 0 | 0 | |
| Debt to equity | 0 | 0 | |
| Debt to assets | 0 | 0 | |
| Net debt to EBITDA | 10.77 | -0.29 | |
| Current ratio | 7.9 | 6.7 | |
| Interest coverage | 0 | -84.56 | |
| Income quality | 0 | -0.03 | |
| Dividend Yield | 0 | 0 | |
| Payout ratio | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | |
| Capex to revenue | 0 | 0 | |
| Capex to depreciation | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | |
| Graham number | 1.1 | 9.57 | |
| ROIC | 0 | -0.02 | |
| Return on tangible assets | 0 | 0.07 | |
| Graham Net | 7.57 | -0.37 | |
| Working capital | 1.63M | 1.27M | |
| Tangible asset value | 134.8M | 131.64M | |
| Net current asset value | -3.2M | -6.38M | |
| Invested capital | 0 | 0 | |
| Average receivables | 0 | 0 | |
| Average payables | 0 | 164.9K | |
| Average inventory | 0 | 0 | |
| Days sales outstanding | 0 | 0 | |
| Days payables outstanding | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | |
| Receivables turnover | 0 | 0 | |
| Payables turnover | 0 | 0 | |
| Inventory turnover | 0 | 0 | |
| ROE | 0 | 0.07 | |
| Capex per share | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0.1 | 0.13 | 0.18 | -0.02 | -0.51 | |
| Operating cash flow per share | -0.01 | 0.03 | -0.02 | -0.01 | -0.02 | |
| Free cash flow per share | -0.01 | 0.03 | -0.02 | -0.01 | -0.02 | |
| Cash per share | 0.04 | 0.07 | 0.04 | 0.04 | 0.03 | |
| Book value per share | 7.36 | 7.42 | 7.49 | -0.43 | -0.82 | |
| Tangible book value per share | 7.36 | 7.42 | 7.49 | 9.22 | 8.89 | |
| Share holders equity per share | 7.36 | 7.42 | 7.49 | -0.43 | -0.82 | |
| Interest debt per share | 0 | 0 | 0 | -0.06 | 0.17 | |
| Market cap | 174.31M | 173.07M | 174.49M | 141.15M | 142.58M | |
| Enterprise value | 173.68M | 171.85M | 173.7M | 140.54M | 142.21M | |
| P/E ratio | 25.19 | 18.68 | 13.95 | -99.4 | -4.91 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -1.13K | 292.78 | -443.24 | -817.79 | -594.35 | |
| PFCF ratio | -1.13K | 292.78 | -443.24 | -817.79 | -594.35 | |
| P/B Ratio | 1.33 | 1.31 | 1.31 | -22.84 | -12.22 | |
| PTB ratio | 1.33 | 1.31 | 1.31 | -22.84 | -12.22 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 100.29 | 184.26 | 124.27 | -119.82 | -29.75 | |
| EV to operating cash flow | -1.13K | 290.71 | -441.24 | -814.22 | -592.78 | |
| EV to free cash flow | -1.13K | 290.71 | -441.24 | -814.22 | -592.78 | |
| Earnings yield | 0.01 | 0.01 | 0.02 | 0 | -0.05 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -0.37 | -1.32 | -0.56 | 0.52 | 0.08 | |
| Current ratio | 3.93 | 6.7 | 9.56 | 0.42 | 0.12 | |
| Interest coverage | -207.9 | -155.89 | -26.26 | 2.43 | -0.92 | |
| Income quality | -0.09 | 0.64 | -0.28 | 0.15 | 0.05 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 4.02 | 4.67 | 5.45 | 0.49 | 3.05 | |
| ROIC | 0 | -0.01 | -0.01 | 0.1 | 0.3 | |
| Return on tangible assets | 0.01 | 0.02 | 0.02 | 0 | -0.05 | |
| Graham Net | -0.43 | -0.37 | -0.3 | -0.45 | -0.83 | |
| Working capital | 720.55K | 1.27M | 921.36K | -1.07M | -3.36M | |
| Tangible asset value | 130.71M | 131.64M | 133.03M | 131.85M | 127.07M | |
| Net current asset value | -7.3M | -6.38M | -5.01M | -6.28M | -11.77M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 54.86K | 106.18K | 109.96K | 51.64K | 497.63K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.01 | 0.02 | 0.02 | 0.06 | 0.62 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
FLACU Frequently Asked Questions
What is Frazier Lifesciences Acquisition Corporation stock symbol ?
Frazier Lifesciences Acquisition Corporation is a US stock , located in Seattle of Wa and trading under the symbol FLACU
What is Frazier Lifesciences Acquisition Corporation stock quote today ?
Frazier Lifesciences Acquisition Corporation stock price is $- today.
Is Frazier Lifesciences Acquisition Corporation stock public?
Yes, Frazier Lifesciences Acquisition Corporation is a publicly traded company.
Company Profile
- Volume Average 4.49K
- Headquarters Seattle,WA,US
- IPO Date 2020-12-09
-
Website
https://www.frazierlifesciencesacquisition.com 
Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.
